Literature summary for 2.3.1.43 extracted from

Ossoli, A.; Simonelli, S.; Varrenti, M.; Morici, N.; Oliva, F.; Stucchi, M.; Gomaraschi, M.; Strazzella, A.; Arnaboldi, L.; Thomas, M.J.; Sorci-Thomas, M.G.; Corsini, A.; Veglia, F.; Franceschini, G.; Karathanasis, S.K.; Calabresi, L.
Recombinant LCAT (lecithin cholesterol acyltransferase) rescues defective HDL (high-density lipoprotein)-mediated endothelial protection in acute coronary syndrome (2019), Arterioscler. Thromb. Vasc. Biol., 39, 915-924 .

Application

Application	Comment	Organism
medicine	the plasma concentration of the LCAT enzyme significantly decreases during ST-segment-elevation myocardial infarction (STEMI) with a parallel significant reduction in LCAT activity. High-density lipoprotein isolated from STEMI patients progressively lose the capacity to promote NO production by endothelial cells, and the reduction is related to decreased LCAT concentration. In vitro incubation of STEMI patients' plasma with recombinant LCAT restores high-density lipoprotein ability to promote endothelial NO production	Homo sapiens

Organism	UniProt	Comment	Textmining
Homo sapiens	P04180	-	-

Source Tissue	Comment	Organism	Textmining
heart	-	Homo sapiens	-

Synonyms	Comment	Organism
LCAT	-	Homo sapiens

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)